Clinical evaluation and patient feedback on the significant efficacy of zolbetuximab

Zolbetuximab (Zolbetuximab) is a monoclonal antibody targeting CLDN18.2 (claudin 18.2). It is mainly used to treat patients with advanced gastric cancer and gastroesophageal junction adenocarcinoma. Its unique mechanism of action makes it an emerging treatment option in the field of gastric cancer. Clinical studies have shown that zotuximab exhibits good anti-tumor activity in CLDN18.2 positive patients, especially when combined with standard chemotherapy regimens, it can significantly improve the progression-free survival and overall survival of patients.

In a pivotal Phase III clinical trial called SPOTLIGHT, researchers combined zotuximab with the CAPOX regimen (capecitabine+oxaliplatin) is used in patients with CLDN18.2-positive gastric cancer who have not received systemic treatment. Compared with chemotherapy alone, the median progression-free survival of patients in the combination treatment group was extended to 10.61 months, and the overall survival was also significantly extended to 18.23 months. These results indicate that zotuximab has strong clinical advantages in improving patient prognosis.

Judging from patient feedback, most patients who received zotuximab combination therapy reported longer disease control times and significant symptom relief, especially improvements in eating difficulties, weight loss, nausea and vomiting. At the same time, patients have good evaluations of its tolerability, and most of the adverse reactions are controllable, mainly including nausea, vomiting, diarrhea and other gastrointestinal discomfort symptoms, which can be relieved after supportive treatment.

Overall, zotuximab, a new targeted therapy, has shown encouraging results in the treatment of patients with specific types of gastric cancer. Its efficacy has been fully verified in clinical trials, and patients' actual experience also shows high satisfaction and compliance. With the maturity of CLDN18.2 detection technology, zotuximab is expected to become an important treatment option for more gastric cancer patients in the future.

Reference materials:https://www.astellas.com/en/news/29401